Inventiva (NASDAQ:IVA) Now Covered by Analysts at TD Cowen

Equities research analysts at TD Cowen began coverage on shares of Inventiva (NASDAQ:IVA) in a report issued on Friday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. TD Cowen’s target price would suggest a potential upside of 266.97% from the stock’s current price.

IVA has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Inventiva in a research report on Thursday, January 30th. UBS Group initiated coverage on Inventiva in a research report on Tuesday, November 12th. They set a “neutral” rating and a $3.00 price objective for the company. Finally, Stifel Nicolaus reduced their price target on Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.60.

Inventiva Price Performance

IVA opened at $2.73 on Friday. Inventiva has a 1 year low of $1.53 and a 1 year high of $4.50. The stock has a fifty day moving average price of $2.32 and a 200 day moving average price of $2.36.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.